Menu Search
Equities

PYC Therapeutics Ltd

PYC:ASX

PYC Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.19
  • Today's Change-0.005 / -2.56%
  • Shares traded813.92k
  • 1 Year change+182.74%
  • Beta0.4175
Data delayed at least 20 minutes, as of Nov 13 2024 03:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year PYC Therapeutics Ltd had net income fall 65.54% from a loss of 22.79m to a larger loss of 37.73m despite a 43.85% increase in revenues from 15.89m to 22.86m.
Gross margin--
Net profit margin-166.75%
Operating margin-164.37%
Return on assets-59.36%
Return on equity-69.70%
Return on investment-69.52%
More ▼

Cash flow in AUDView more

In 2024, PYC Therapeutics Ltd increased its cash reserves by 329.47%, or 51.30m. Cash Flow from Financing totalled 90.19m or 394.63% of revenues. In addition the company used 38.59m for operations while cash used for investing totalled 307.04k.
Cash flow per share-0.0093
Price/Cash flow per share--
Book value per share0.017
Tangible book value per share0.0162
More ▼

Balance sheet in AUDView more

PYC Therapeutics Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 66.87m.
Current ratio9.40
Quick ratio--
Total debt/total equity0.0138
Total debt/total capital0.0135
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.